Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash & Current Investments (2016 - 2025)

Integra Lifesciences Holdings' Cash & Current Investments history spans 17 years, with the latest figure at $263.7 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 3.59% year-over-year to $263.7 million; the TTM value through Dec 2025 reached $263.7 million, down 3.59%, while the annual FY2025 figure was $263.7 million, 3.59% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $263.7 million at Integra Lifesciences Holdings, up from $232.2 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $663.1 million in Q1 2024 and bottomed at $232.2 million in Q3 2025.
  • The 5-year median for Cash & Current Investments is $308.3 million (2023), against an average of $370.6 million.
  • The largest annual shift saw Cash & Current Investments skyrocketed 115.74% in 2024 before it crashed 58.79% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $513.4 million in 2021, then increased by 7.83% to $553.6 million in 2022, then plummeted by 49.86% to $277.6 million in 2023, then dropped by 1.45% to $273.6 million in 2024, then decreased by 3.59% to $263.7 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Cash & Current Investments are $263.7 million (Q4 2025), $232.2 million (Q3 2025), and $253.6 million (Q2 2025).